Kevin A. David
A5013911840- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Histone Deacetylase Inhibitors Research
- Cancer Immunotherapy and Biomarkers
- Frailty in Older Adults
- Immune Cell Function and Interaction
- Multiple and Secondary Primary Cancers
- interferon and immune responses
- Bladder and Urothelial Cancer Treatments
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Polyomavirus and related diseases
- Retinoids in leukemia and cellular processes
- Esophageal Cancer Research and Treatment
- Biosimilars and Bioanalytical Methods
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Cytokine Signaling Pathways and Interactions
- T-cell and Retrovirus Studies
- Cutaneous lymphoproliferative disorders research
Rutgers, The State University of New Jersey
2016-2025
Rutgers Cancer Institute of New Jersey
2011-2024
Memorial Sloan Kettering Cancer Center
2023-2024
Johnson University
2021-2022
Cancer Institute of Florida
2020-2022
Robert Wood Johnson University Hospital
2021
Rush University Medical Center
2010-2019
Northwestern University
2007-2016
Cornell University
2006-2010
NewYork–Presbyterian Hospital
2007-2010
PURPOSE Adult post-transplantation lymphoproliferative disease (PTLD) has a reported 3-year overall survival (OS) of 35% to 40%. The impact rituximab on the outcome PTLD is not well defined. METHODS We examined clinical features and outcomes among large cohort solid organ transplantation (SOT) -related patients with who were recently treated at four Chicago institutions (from January 1998 2008). Results Eighty identified had median SOT-to-PTLD time 48 months (range, 1 216 months). All...
Studies of perioperative chemotherapy for muscle invasive bladder cancer have shown a survival benefit with combined modality therapy. We reviewed use in patients stage III transitional cell carcinoma the from 1998 to 2003 evaluate treatment patterns.The National Cancer Data Base collected data on approximately 60% all newly diagnosed cases United States 2003. queried male and female 18 years old or older between A total 224,060 records were reviewed. Perioperative was defined as given...
Chimeric antigen receptor (CAR) T-cell (CAR-T) immunotherapy is an effective therapy for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). However, data are limited on the impact of convergence race and social determinants health outcomes patients treated with CAR-T therapy. We examined interactions between insurance type care use in aggressive B-NHL. Adult r/r B-NHL CD19 CAR-Ts were identified 2015 2021 across 13 US academic centers. Insurance type, demographic, clinical...
We investigated the cytotoxicity and mechanisms of cell death broad-spectrum histone deacetylase (HDAC) inhibitor PCI-24781, alone combined with bortezomib in Hodgkin lymphoma non-Hodgkin lines primary lymphoproliferative (CLL/SLL) cells.Apoptosis, mitochondrial membrane potential, cycle analysis, reactive oxygen species (ROS) were measured by flow cytometry, whereas caspase activation was determined Western blot. Nuclear factor kappaB (NF-kappaB)-related mRNAs quantified reverse...
Abstract Purpose: Andrographolide is a diterpenoid lactone isolated from Andrographis paniculata (King of Bitters), an herbal medicine used in Asia. It has been reported to have anti-inflammatory, antihypertensive, antiviral, and immune-stimulant properties. Furthermore, it shown inhibit cancer cell proliferation induce apoptosis leukemia solid tumor lines. Experimental Design: We studied the Burkitt p53-mutated Ramos line, mantle lymphoma (MCL) line Granta, follicular (FL) HF-1, diffuse...
Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel agents are approved to treat relapsed, refractory B-NHL; however, it remains unclear how sequence these therapies pre- and post-CAR-T. We conducted multicenter retrospective analysis describe peri-CAR-T practice patterns survival predictors CD19-directed CAR-T. Patients (n = 514) from 13 centers treated with CAR-T...
There is a paucity of large-scale data delineating outcomes and prognostication older patients with primary central nervous system lymphoma (PCNSL). We retrospectively analyzed 539 newly-diagnosed PCNSL ages ≥60 years across 20 U.S. academic centers. The median age was 70 (range 60-88); at least one geriatric syndrome present in 46%; the Cumulative Index Ratings Scale-Geriatrics (CIRS-G) score 6 (range, 0-27); 36% had impairment activities daily living (ADL). most common induction regimens...
We provide evidence for the existence of an IFN-regulated cellular pathway involving mitogen-activated protein kinase (MAPK)-integrating (Mnk) 1. Our data demonstrate that type I (alpha, beta) IFNs induce phosphorylation/activation Mnk1, which, in turn, regulates phosphorylation eukaryotic initiation factor 4E (eIF4E) on Ser-209. Such Mnk activation depends upstream engagement Jak1, and requires downstream Mek/Erk MAPK pathway. In studies using double Mnk1-/-Mnk2-/- knockout mouse embryonic...
No AccessJournal of UrologyAdult Urology1 May 2011Transitional Cell Carcinoma the Bladder: Racial and Gender Disparities in Survival (1993 to 2002), Stage Grade 2007) Katherine Mallin, Kevin A. David, Peter R. Carroll, Matthew I. Milowsky, David M. Nanus MallinKatherine Mallin American College Surgeons, Chicago, Illinois , DavidKevin Cancer Institute New Jersey, University Medicine Dentistry Brunswick, Jersey CarrollPeter Carroll Department Urology, California-San Francisco, San California...
Targeted therapies and checkpoint blockade therapy (CBT) have shown efficacy for patients with Hodgkin lymphoma (HL) in the relapsed refractory (R/R) setting, but once discontinued owing to progression or side effects, it is unclear how successful further will be. Moreover, there are no data on optimal sequencing of these treatments standard other novel agents. In a multicenter, retrospective analysis, we investigated whether exposure CBT could sensitize HL subsequent therapy.Seventeen...
Autologous stem cell transplantation (ASCT) can be curative for patients with relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 monoclonal antibodies (mAbs) sensitize to subsequent chemotherapy, we hypothesized therapy before ASCT would result in acceptable outcomes among high-risk who progressed or responded insufficiently ≥1 salvage regimen, including chemorefractory are traditionally considered poor candidates. We retrospectively identified 78 HL...
Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this prognostic impact. In multicenter retrospective study, we sought to confirm observation by evaluating survival outcomes among patients relapsed/refractory DHL DEL treated evaluate of relapse post-CART. A total 408 adult from 13 academic centers were included based on the availability DEL. All in (n = 80) vs non-DHL 328) analysis, while 333 analysis 74) non 179). On MVA,...
Abstract BACKGROUND: Previous investigators have detected shifts to lower stages at diagnosis for renal cell carcinoma and prostate cancer. The authors investigated whether a similar pattern is seen urothelial carcinomas of the bladder, ureter, pelvis sought identify changes in cancer grade survival trends from 1993 2005. METHODS: National Cancer Data Base (NCDB) collects data on approximately 75% all newly diagnosed cases annually. queried database 1993‐2005 patients aged 18 years older....
Central nervous system (CNS) involvement in Burkitt lymphoma (BL) poses a major therapeutic challenge, and the relative ability of contemporary regimens to treat CNS remains uncertain. We described prognostic significance incidence recurrence/progression after immunochemotherapy using real-world clinicopathologic data on adults with BL diagnosed between 2009 2018 across 30 US institutions. examined associations baseline involvement, patient characteristics, complete response (CR) rates,...
Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed validated novel index specific for BL to aid risk stratification, interpretation of trials, targeted development treatment approaches.We derived the International Prognostic Index (BL-IPI) from real-world data set adult patients with treated immunochemotherapy in United States between 2009 2018, identifying candidate variables that showed strongest association progression-free...
Abstract Clinical trials of novel salvage therapies have encouraging outcomes for relapsed/refractory transplant‐eligible classic Hodgkin lymphoma (R/R cHL) but comparison with conventional chemotherapy is lacking. Herein, we report the final analysis a multicenter retrospective cohort R/R cHL assessing by type therapy before autologous stem cell transplant (ASCT). patients who underwent ASCT at 14 institutions across United States were included. Outcomes compared among receiving...